Molecular profiling of gliomas: potential therapeutic implications.

about

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma.Molecular markers in glioma.

P2860

Q36201736-545E8DD9-72F0-44FC-81B9-5782C2DD0B1D Q36341179-B55EDF12-3FB6-47E2-B041-724E0BF0C676 Q39148751-24373977-1B6B-4757-8589-D96BFFEAA78E

P2860

Molecular profiling of gliomas: potential therapeutic implications.

Item

http://www.wikidata.org/entity/Q38539422

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Molecular profiling of gliomas: potential therapeutic implications.

@en

type

Item

label

Molecular profiling of gliomas: potential therapeutic implications.

@en

prefLabel

Molecular profiling of gliomas: potential therapeutic implications.

@en

P1476

Molecular profiling of gliomas: potential therapeutic implications

@en

P2093

Alberto Duran-Peña

http://www.w3.org/2001/XMLSchema#string

Sandeep C Pingle

http://www.w3.org/2001/XMLSchema#string

Santosh Kesari

http://www.w3.org/2001/XMLSchema#string

P2860

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

P304

955-962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1062368

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David E Piccioni

Ahmed Idbaih

A Alentorn

P577

2015-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26118895

http://www.w3.org/2001/XMLSchema#string

Molecular profiling of gliomas: potential therapeutic implications.

about

P2860

P2860

Molecular profiling of gliomas: potential therapeutic implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698